{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 85 of 169', 'Other action taken: any other action taken as a result of the AE must be recorded (none,', 'concomitant medication, concomitant procedure).', 'Withdrawn due to AE: it must be recorded whether the AE leads to withdrawal from the trial.', '11.3 Reporting of serious adverse events', 'The criteria that define an AE as serious (i.e., an SAE) are defined in Appendix 2.', '11.3.1 Investigator reporting responsibilities', 'Any SAE must be reported to LEO on the (paper) SAE Form within 24 hours of first', 'knowledge. This report should contain an assessment of available information on seriousness,', 'severity, causal relationship to the IMP, comparator or trial procedure, the action taken, the', 'outcome to date, and a narrative description of the course of the event.', 'The completed SAE form must be faxed or scanned and e-mailed to Global', 'Pharmacovigilance, LEO using the e-mail address or fax number below:', 'Global Pharmacovigilance, LEO', 'E-mail address: drug.safety@leo-pharma.com', 'Fax number: +45 7226 3287', 'It may be relevant for the investigator to enclose other information with the SAE form, such', 'as anonymised reports of diagnostic procedures, hospital records, autopsy reports, etc.', 'Additionally, Global Pharmacovigilance, LEO may request further information in order to', 'fully assess the SAE. The investigator must forward such information to LEO upon request by', 'fax or e-mail (see contact details above).', 'The investigator must notify the local institutional review board(s) (IRB independent', 'ethics committee(s) (IEC of SAEs as required by current applicable legislation for the', 'concerned country.', 'SAEs occurring after the completion of the clinical trial (i.e., after the safety follow-up visit', '[FU1/FU2]) should not be routinely sought or collected. However, such events should be', 'reported to LEO (see contact details above) if the investigator becomes aware of them.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 86 of 169', '11.3.2 LEO reporting responsibilities', 'Global Pharmacovigilance, LEO is responsible for assessing whether or not an SAE is', 'expected. The relevant reference document for this clinical trial is:', \"For the IMP, the Investigator's Brochure, edition 16 and subsequent updates must be used.\", 'Global Pharmacovigilance, LEO will notify the regulatory authorities and concerned', 'investigators of SAEs according to the current applicable legislation for the concerned', 'countries.', 'The IRB(s)/IEC(s) will be notified of SAEs according to the current applicable legislation for', 'the concerned countries.', 'For all countries except the US, all SAEs which are assessed as causally related to the IMP(s)', 'by either the investigator or LEO (ICH E2A Guideline), and which are unexpected', '(Suspected, Unexpected Serious Adverse Reactions [SUSARs]), are subject to expedited', 'reporting to regulatory authorities and IRB(s)/IEC(s) according to the current applicable', 'legislation in the concerned countries. Investigators will be notified of such SUSARs and the', 'evolving safety profile on an ongoing basis.', 'For the US, as per Guidance for Industry and Investigators - Safety Reporting Requirements', 'for INDs and BA/BE Studies, only those events for which the sponsor determines there is a', 'reasonable possibility of a causal relationship are subject to IND Safety Reporting.', 'Investigators will be notified of the evolving safety profile on an ongoing basis.', '11.4 Other events that require expedited reporting', '11.4.1 Pregnancy', 'Any pregnancy occurring during the clinical trial must be reported to LEO within 24 hours of', 'first knowledge using the (paper) Pregnancy Follow Up Form (Part I). All such pregnancies', 'must be followed up until delivery or termination and final outcome must be reported on the', '(paper) Pregnancy Follow Up Form (Part II) within 24 hours of first knowledge.', 'The completed Pregnancy Follow Up Forms must be faxed or scanned and e-mailed to Global', 'Pharmacovigilance, LEO. Contact details are given in Section 11.3.1.', 'Pregnant subjects must permanently discontinue IMP (see Section 9.8.1).', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}